Payment overview · 2025
General Payments
$121.83
6 reported records · 4 companies
Healthcare provider profile · identity verified
Jamshid Faraji, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CARMICHAEL, CA · NPI 1932125382
Verified facts
What the public records show
CMS Open Payments records show Jamshid Faraji, M.D. received $121.83 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 41.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.99 | 41.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.14 | 30.5% | 2 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $17.64 | 14.5% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $17.06 | 14.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $121.83 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $49.99 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.14 | 2 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $17.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 88 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 97 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
88 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
97 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 685 | 143 |
| Levothyroxine Sodium | Levothyroxine Sodium | 438 | 79 |
| Amlodipine Besylate | Amlodipine Besylate | 347 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 298 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 44 |
| Ezetimibe | Ezetimibe | 201 | 43 |
| Potassium Chloride | Potassium Chloride | 200 | 39 |
| Losartan Potassium | Losartan Potassium | 198 | 48 |
| Furosemide | Furosemide | 182 | 42 |
| Metformin Hcl Er | Metformin Hcl | 181 | 36 |
| Lisinopril | Lisinopril | 180 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 42 |
| Ozempic | Semaglutide | 173 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 170 | 36 |
| Omeprazole | Omeprazole | 165 | 31 |
| Gabapentin | Gabapentin | 155 | 29 |
| Meloxicam | Meloxicam | 136 | 19 |
| Metformin Hcl | Metformin Hcl | 134 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 133 | 37 |
| Jardiance | Empagliflozin | 129 | 31 |
| Allopurinol | Allopurinol | 122 | 23 |
| Famotidine | Famotidine | 122 | 21 |
| Icosapent Ethyl | Icosapent Ethyl | 121 | 24 |
| Montelukast Sodium | Montelukast Sodium | 118 | 24 |
| Celecoxib | Celecoxib | 117 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 13 |
| Carvedilol | Carvedilol | 108 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 21 |
| Spironolactone | Spironolactone | 101 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 97 | 22 |
| Trazodone Hcl | Trazodone Hcl | 96 | 15 |
| Finasteride | Finasteride | 93 | 13 |
| Bumetanide | Bumetanide | 88 | 17 |
| Linzess | Linaclotide | 88 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 87 | 19 |
| Chlorthalidone | Chlorthalidone | 85 | 22 |
| Eliquis | Apixaban | 85 | 22 |
| Simvastatin | Simvastatin | 85 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 83 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 72 | 15 |
| Ramipril | Ramipril | 71 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 11 |
| Vascepa | Icosapent Ethyl | 68 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 16 |
| Azelastine Hcl | Azelastine Hcl | 61 | 13 |
| Alprazolam | Alprazolam | 60 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 59 | 12 |
| Olanzapine | Olanzapine | 59 | suppressed |
| Levetiracetam | Levetiracetam | 55 | suppressed |
| Pregabalin | Pregabalin | 55 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 54 | suppressed |
| Lorazepam | Lorazepam | 53 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | suppressed |
| Trulicity | Dulaglutide | 52 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 51 | suppressed |
| Mirtazapine | Mirtazapine | 50 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 50 | suppressed |
| Metolazone | Metolazone | 49 | 11 |
| Kerendia | Finerenone | 48 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | suppressed |
| Prednisone | Prednisone | 47 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | suppressed |
| Baclofen | Baclofen | 44 | suppressed |
| Atenolol | Atenolol | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 13 |
| Synjardy | Empagliflozin/Metformin Hcl | 43 | suppressed |
| Azithromycin | Azithromycin | 42 | 35 |
| Cilostazol | Cilostazol | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 11 |
| Clonidine Hcl | Clonidine Hcl | 40 | suppressed |
| Glimepiride | Glimepiride | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 39 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | 12 |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 38 | 27 |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 35 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Valsartan | Valsartan | 34 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Latanoprost | Latanoprost | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Clonidine | Clonidine | 28 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 28 | suppressed |
| Movantik | Naloxegol Oxalate | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 19 |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Testosterone | Testosterone | 27 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Repaglinide | Repaglinide | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Creon | Lipase/Protease/Amylase | 23 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 23 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 18 |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 12 |
| Lidocaine | Lidocaine | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 16 |
| Pitavastatin Calcium | Pitavastatin Calcium | 16 | suppressed |
| Erythromycin | Erythromycin Base | 15 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Steglujan | Ertugliflozin/Sitagliptin Phos | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $121.83 · 6 records | ABBVIE INC. | APTIMA, LINZESS, SMARTVEST, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error